Astrazeneca (AZN) confirmed Friday in an emailed statement to MT Newswires that its breast cancer treatment Enhertu and cancer treatment Orpathys have been added to China's National Reimbursement Drug List (NRDL)
The inclusion in the NRDL grants state-run medical insurance coverage to the cancer treatments, starting Jan. 1, 2025, multiple media outlets reported Thursday.
Enhertu is among 91 drugs that will be added to the NRDL, including oncology drugs from drugmakers including Johnson & Johnson (JNJ), Merck (MRK), Bristol Myers (BMY), Roche and Sanofi (SNY), Bloomberg said and added that drugmakers have to accept price cuts, averaging 63%, to secure inclusion on the list.
Zai Lab (ZLAB) said Thursday its AUGTYRO was also included in the NRDL to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。